Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/32451
Title: The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation
Authors: FRUCHART, Jean-CharlesSANTOS, Raul D.AGUILAR-SALINAS, CarlosAIKAWA, MasanoriRASADI, Khalid AlAMARENCO, PierreBARTER, Philip J.CESKA, RichardCORSINI, AlbertoDESPRES, Jean-PierreDURIEZ, PatrickECKEL, Robert H.EZHOV, Marat V.FARNIER, MichelGINSBERG, Henry N.HERMANS, Michel P.ISHIBASHI, ShunKARPE, FredrikKODAMA, TatsuhikoKOENIG, WolfgangKREMPF, MichelLIM, SooLORENZATTI, Alberto J.MCPHERSON, RuthNUNEZ-CORTES, Jesus MillanNORDESTGAARD, Borge G.OGAWA, HisaoPACKARD, Chris J.PLUTZKY, JorgePONTE-NEGRETTI, Carlos I.PRADHAN, ArunaRAY, Kausik K.REINER, ZeljkoRIDKER, Paul M.RUSCICA, MassimilianoSADIKOT, ShaukatSHIMANO, HitoshiSRITARA, PiyamitrSTOCK, Jane K.SU, Ta-ChenSUSEKOV, Andrey V.TARTAR, AndreTASKINEN, Marja-RiittaTENENBAUM, AlexanderTOKGOZOGLU, Lale S.TOMLINSON, BrianTYBJAERG-HANSEN, AnneVALENSI, PaulVRABLIK, MichalWAHLI, WalterWATTS, Gerald F.YAMASHITA, ShizuyaYOKOTE, KoutaroZAMBON, AlbertoLIBBY, Peter
Citation: CARDIOVASCULAR DIABETOLOGY, v.18, article ID 71, 20p, 2019
Abstract: In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARM) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARM agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARM agonist safely reduces residual cardiovascular risk.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCP
Departamento de Cardio-Pneumologia - FM/MCP

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor


Files in This Item:
File Description SizeFormat 
art_SANTHIAGO_Validation_of_the_Percent_Tissue_Altered_as_a_2019.PDF
  Restricted Access
publishedVersion (English)298.63 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.